Image

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

Weekly study of HIV-1 treatment with Islatravir and Ulonivirine.

Recruiting
18 years and older
All
Phase 2
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study is exploring a new once-a-week treatment for HIV-1, combining Islatravir (ISL) and Ulonivirine (ULO). Researchers want to see if this treatment is as effective as the daily pill, BIC/FTC/TAF. They will check this by measuring how many people still have a high virus level in their blood after 24 weeks. They will also assess the safety of the new treatment and how well people tolerate it.

  • Study Duration: 24 weeks
  • Eligibility: Participants must have been on the current treatment BIC/FTC/TAF with good virus control for at least 6 months.
  • Exclusions: People with HIV-2, active AIDS-related infections, hepatitis C or B, certain recent cancers, or previous use of ISL/ULO cannot join.

Participants should understand the study involves trying a new treatment, which may carry unknown risks. Before joining, they should consider the benefits of a weekly dose compared to the daily routine, and the commitment to attend study visits. Always consult your healthcare provider before enrolling in a clinical study.

Print
Study details
    Human Immunodeficiency Virus Type 1 (HIV-1) Infection

NCT06891066

Merck Sharp & Dohme LLC

10 May 2025

Contact a study center
Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

  Other languages supported:

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.